25Mar 2017

SIMVASTATIN AS A SOLE OSTEOPROMOTIVE MATERIAL IN CRITICALLY SIZED BONE DEFECTS: SYSTEMATIC REVIEW.

  • Assistant lecturer, Oral and Maxillofacial surgery department, Cairo University, Cairo, Egypt.
  • Assistant researcher, prosthodontics department, National research center, Cairo, Egypt.
  • Assistant professor, Oral and Maxillofacial surgery Department, Cairo University, Cairo, Egypt.
  • Professor, Oral and Maxillofacial surgery Department, Cairo University, Cairo, Egypt.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Objective: The aim of this study is to evaluate the effect of simvastatin as a sole osteoinductive material on bone formation by eliminating the role that may be attributed to the various bone grafts that have been used with simvastatin as drug carriers. Material and methods: The search terms (Simvastatin) AND (Bone Defect) were used to search the PUBMED electronic database. In addition to this online search, a hand search of the relevant major international journals was also performed. Results: The search results showed total of 46 articles, only 3 articles were found to fulfill the inclusion criteria. Two out of these 3 articles used the same simvastatin concentration (0.2ml simvastatin solution on either collagen or gelatin sponge) while in the third article, collagen graft of swine origin was used with two different simvastatin dose (2.2 mg and 0.5 mg).Simvastatin seems to have osteoinductive potentials when applied locally in bone defects when used in proper dose and with proper carrier.Conclusion:The safety and osteoinductive properties of simvastatin are directly affected by the used dose and carrier, thus further studies are needed in order to determine the ideal dose/carrier complex that maximize the osteoinductive capabilities and eliminate or minimize the associated inflammatory reaction.

  1. Gerressen M, Hermanns-Sachweh B, Riediger D, et al. Purely cancellous vs. corticocancellous bone in sinus floor augmentation with autogenous iliac crest: a prospective clinical trial. Clin Oral Impl Res.2009; 20:109-15.
  2. Arrington ED, Smith WJ, Chambers HG, et al. Complications of iliac crest bone graft harvesting. ClinOrthopRelat Res.1996; 329:300-309.
  3. Cordaro L, Amade,D.S , Cordaro, M. Clinical results of alveolar ridge augmentation with mandibular block bone grafts in partially edentulous patients prior to implant placement. Clinical Oral Implants Research.2002; 13: 103?111.
  4. Nkenke E, Stelzle F. Clinical outcomes of sinus floor augmentation for implant placement using autogenous bone or bone substitutes: a systematic review. Clin Oral Implants Res.2009; 20:124-133.
  5. Precheur HV. Bone Graft Materials. Dent Clin N Am.2007; 51: 729?746.
  6. Wheeler SL. Sinus augmentation for dental implants: the use of alloplastic materials. J Oral Maxillofac Surg.1997; 55:1287-1293.
  7. Uludag H, D?Augusta D, Golden J, et al. Implantation of recombinant human bone morphogenetic proteins with biomaterial carriers: a correlation between protein pharmacokinetics and osteoinduction in the rat ectopic model. J Biomed Mater Res. 2000; 50:227-38.
  8. Gruber RM, A. Ludwig A, Merten HA, et al. Sinus floor augmentation with recombinant human growth and differentiation factor-5 (rhGDF-5): a pilot study in the Goettingen miniature pig comparing autogenous bone and rhGDF-5. Clin Oral Implants Res.2009; 20:175-182.
  9. Boyne PJ. Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J Bone Joint Surg Am. 2001; 83: 146? 150.
  10. Schliephake H. Bone growth factors in maxillofacial skeletal reconstruction. Int J OralMaxillofac Surg. 2002; 31:469?484
  11. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000; 101: 207-213.
  12. Nyan M, Sato D, Kihara H, et al. Effects of the combination with α-tricalcium phosphate and simvastatin on bone regeneration. Clin. Oral Impl. Res.2009; 20: 280?287.
  13. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999; 286:1946?9.
  14. Davignon J, Laaksonen R: Low-density lipoprotein-independent effects of statins. CurrOpinLipidol. 1999; 10: 543-559.
  15. Bellosta S, Ferri N, Bernini F, et al. Non-lipid related effects of statins. Ann Med. 2000; 32: 164-176.
  16. Nyan M, Miyahara T, Noritake K, Hao J, Rodriguez R, Kuroda S. Molecular and tissue responses in the healing of rat calvarial defects after local application of simvastatin combined with alpha tricalcium phosphate. J Biomed Mater Res B ApplBiomater .2010; 93:65-73.
  17. Calixto JC, Lima CE, Frederico L, et al. The influence of local administration of simvastatin in calvarial bone healing in rats. J Craniomaxillofac Surg. 2011; 39:215-20.
  18. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007; 127: 514?525.
  19. Menke NB, Ward KR, Witten TM, et al. Impaired wound healing.?2007; 25: 19?25.
  20. Wong RW, Rabie AB. Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofac Surg.2003; 41:244-8.
  21. Rojbani H, Nyan M, Ohya K, et al. Evaluation of the osteoconductivity of α-tricalcium phosphate, β-tricalcium phosphate, and hydroxyapatite combined with or without simvastatin in rat calvarial defect. J Biomed Mater Res A. 2011; 98:488?498.
  22. ?ze? I,?Kili? E,?G?m?ş C,?G?zeF.Effect?of?local?simvastatin?application?on mandibular?defects. J Craniofac Surg.2007; 18:546-50.
  23. Allon I, Anavi Y, Allon DM. Topical simvastatin improves the proangiogenic and pro-osteogenic properties of bioglass putty in the rat calvaria critical-size model. J Oral Implantol.2014; 40:251-258.
  24. Thylin MR, McConnell JC, Schmid MJ, et al. Effects of simvastatin gels on murine calvarial bone. J Periodontol .2002; 73:1141?1148.
  25. Stein D, Lee Y, Schmid MJ, et al. Local simvastatin effects on mandibular bone growth and inflammation. J Periodontol .2005; 76:1861?1870.
  26. Sugiyama M, Kodama T, Konishi K, et al. (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. BiochemBiophys Res Commun.2000; 271:688-692.
  27. Ohnaka K, Shimoda S, NawataH,et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. BiochemBiophys Res Commun. 2001; 287:337-342.
  28. Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology .2003; 144:681-692.
  29. Gutierrez GE, Lalka D, Garrett IR, et al. Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. OsteoporosInt .2006; 17:1033?1042.
  30. Rogers MJ. Statins: lower lipids and better bones? Nat Med.2000; 6: 21- 23.

[Ayman Gouda, Eman Helal, Saleh Bakry and Salah Yassin. (2017); SIMVASTATIN AS A SOLE OSTEOPROMOTIVE MATERIAL IN CRITICALLY SIZED BONE DEFECTS: SYSTEMATIC REVIEW. Int. J. of Adv. Res. 5 (Mar). 549-553] (ISSN 2320-5407). www.journalijar.com

Ayman Gouda
1) Assistant lecturer, Oral and Maxillofacial surgery department, Cairo University, Cairo, Egypt

DOI:

Article DOI: 10.21474/IJAR01/3543      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3543

Download Full Paper

Download PDF No. of Downloads: 17 | No. of Views: 111